IFP Advisors’s Coherus Oncology CHRS Stock Holding History

IFP Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$50	Sell	41 -483	-92%	-$661	﹤0.01%	5063
2026 Q2	$734	Sell	524 -86	-14%	-$140	﹤0.01%	4596
2026 Q1	$1.03K	Sell	610 -68	-10%	-$121	﹤0.01%	4209
2025 Q4	$963	Buy	678 +291	+75%	+$424	﹤0.01%	4085
2025 Q3	$635	Buy	387 +10	+3%	+$11	﹤0.01%	4103
2025 Q2	$276	Buy	377 +153	+68%	+$132	﹤0.01%	4572
2025 Q1	$181	Hold	224	–	–	﹤0.01%	3693
2024 Q4	$309	Buy	+224	New	+$251	﹤0.01%	3560
2023 Q1	–	Sell	-1,000	Closed	-$16K	–	3540
2022 Q4	$16K	Buy	+1,000	New	+$7.69K	﹤0.01%	3057
2022 Q1	–	Sell	-53	Closed	-$1K	–	4550
2021 Q4	$1K	Buy	+53	New	+$927	﹤0.01%	2959
2021 Q1	–	Sell	-18	Closed	-$306	–	3027
2020 Q4	$0	Sell	18 -17	-49%	-$303	﹤0.01%	2959
2020 Q3	$0	Buy	+35	New	+$651	﹤0.01%	2852
2020 Q2	–	Sell	-161	Closed	-$2.72K	–	2757
2020 Q1	$3K	Buy	161 +21	+15%	+$388	﹤0.01%	2232
2019 Q4	$3K	Hold	140	–	–	﹤0.01%	2352
2019 Q3	$3K	Buy	+140	New	+$2.8K	﹤0.01%	2517

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

IFP Advisors's CHRS Position: Q3 2026 in Review

IFP Advisors reduced its Coherus Oncology (CHRS) stake by 92% in Q3 2026, selling an estimated $661 and leaving 41 shares worth $50. The position accounts for ﹤0.01% of the portfolio, ranked #5063.

IFP Advisors first reported a position in CHRS in Q3 2019 and has held it in 15 quarters since. The position peaked at $16K in Q4 2022. 75 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

IFP Advisors held 41 shares of Coherus Oncology worth $50 as of Q3 2026.
IFP Advisors sold 483 Coherus Oncology shares in Q3 2026, an estimated $661.
Coherus Oncology made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5063 holding.
IFP Advisors first reported a position in Coherus Oncology in Q3 2019 and has held it in 15 quarters since.
IFP Advisors's Coherus Oncology position peaked at $16K in Q4 2022.
75 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.